Trials / Completed
CompletedNCT02086604
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brentuximab vedotin | |
| DRUG | Lenalidomide |
Timeline
- Start date
- 2014-09-18
- Primary completion
- 2017-06-09
- Completion
- 2022-01-12
- First posted
- 2014-03-13
- Last updated
- 2022-02-17
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02086604. Inclusion in this directory is not an endorsement.